ClinicalTrials.gg
Not yet recruitingNCT07849985Updated Sep 30, 2026

Anhedonia Beyond Depressive Symptoms in Children and Adolescents With Conduct Disorder

An observational study in Conduct Disorder and Depression, sponsored by Assiut University. Not yet recruiting. Open to participants aged 12 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Assiut University · Observational

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
90
Ages
12 Years to 17 Years
Sex
All
01

Study summary

Conduct Disorder (CD) is a common psychiatric disorder among children and adolescents and is characterized by a persistent pattern of behaviors that violate the rights of others or major age-appropriate social norms and rules. Although CD is traditionally classified as an externalizing disorder, evidence suggests that some affected adolescents also show abnormalities in emotional and motivational processing, particularly in reward and punishment responsiveness. Anhedonia, defined as reduced ability to experience pleasure, is traditionally considered a core symptom of depression but is increasingly recognized as a transdiagnostic construct that may reflect disturbances in reward processing. Importantly, altered reward responsiveness is not synonymous with clinical anhedonia, and clinically measured anhedonia in adolescents with CD remains insufficiently characterized. Depressive symptoms may contribute to anhedonia and therefore require assessment and statistical control. ADHD is also frequently comorbid with CD and may independently influence reward processing and motivation. Callous-Unemotional traits may additionally overlap with emotional blunting. Therefore, the present study will compare anhedonia in adolescents with CD with or without comorbid ADHD, and healthy controls, while accounting for depressive symptoms and relevant clinical covariates.

02

Conditions studied

  • Conduct Disorder
  • Depression
03

In context

Conduct Disorder

101 studies on the registry are indexed under Conduct Disorder; 15 are open to participants now.

This study's planned enrollment of 90 is below the median of 230 across 17 observational studies indexed under Conduct Disorder.

Browse Conduct Disorder studies →

Lead sponsor

Assiut University is the lead sponsor of 5,081 studies on the registry; 2,179 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Participants aged 12-17 years will be recruited consecutively from the outpatient child and adolescent psychiatry service. Participants meeting criteria for Conduct Disorder will form the clinical group. Healthy controls of comparable age, sex, and socioeconomic status will be recruited from community or school settings. ADHD comorbidity will be assessed within the Conduct Disorder group

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 12-17 years.

    • CD groups: meeting criteria for Conduct Disorder confirmed using the Arabic K-SADS-PL-C DSM-5.
    • Control group: no current or previous psychiatric diagnosis according to the Arabic K-SADS-PL-C DSM-5.
    • Ability to understand and complete the assessment procedures.
    • Written from a parent/legal guardian and written assent from the adolescent.

Exclusion criteria

Exclusion Criteria:

    • Intellectual disability or severe cognitive impairment interfering with reliable assessment.

      • Autism spectrum disorder or severe neurodevelopmental disorder interfering with self-report.
      • Current psychotic disorder.
      • Current or past bipolar I disorder or manic episode.
      • Current major depressive episode meeting full diagnostic criteria.
      • Current severe substance use disorder.
      • Known neurological disorder, including epilepsy or severe traumatic brain injury.
      • Major uncontrolled medical condition likely to substantially affect mood or hedonic functioning.
      • Current medication expected to substantially affect reward processing or anhedonia, where .
      • Acute suicidal risk or psychiatric condition requiring immediate crisis intervention/hospitalization.
      • Refusal to participate or inability to complete the assessment. Stable stimulant treatment for ADHD may be permitted when clinically necessary and will be recorded as a covariate.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
90 participants (estimated)
Patient registry
No

Groups and cohorts

  • cases group

    Participants meeting criteria for Conduct Disorder

  • control group

    healthy control

06

What researchers measure

Primary outcomes

  1. SHAPS total score

    SHAPS total score, representing overall anhedonia severity

    Time frame: baseline

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2026, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartEst.
Oct 2026
Primary completionEst.
Oct 2026
CompletionEst.
Dec 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07849985
Lead sponsor
Assiut University
Responsible party
Katreen Maher (residant doctor at Assiut university hospital, Assiut University) — Principal investigator
First posted
Sep 30, 2026
Start date
Oct 2026 (estimated)
Primary completion
Oct 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion